Biotechnology is becoming hot again. It is no secret that we are bullish on biotech.
Biotech companies have a track record of being very volatile, similar to gold stocks for instance. In an uptrend, they can easily rise multifolds. When biotech sold off last year, however, biotech companies truly collapsed in a matter of 3 to 6 months.
An important indicator of a company’s health is its ability to stand strong during a market correction.
One of the biotech companies which has done great since last year’s correction(s) is BioTime, symbol BTX. Quite some positive news hit the wires recently, including the news that USC neuroscientists announced historic news about BioTime’s (BTX) stem cell platform, as, for the first time, a quadriplegic patient with complete injury to the spinal cord has substantially recovered.
In an investor update, the CEO wrote: “News that was released this morning by the University of Southern California offers hope to patients suffering from severe spinal cord injury. A team of doctors at USC are evaluating the safety and efficacy of AST-OPC1 as a therapy for spinal cord injuries. As reported, a paralyzed patient in the study regained the use of his arms and hands after treatment with AST-OPC1 in April. Asterias announced that it expects to report its interim efficacy data on September 14, during the 55th Annual Scientific Meeting of the International Spinal Cord Society (ISCoS), which is being held in Vienna, Austria.”
Financially, the company is in good shape, given $20M loss on Dec 31st 2015, profits of $24M on June 30th and $27M in cash on June 30th. Moreover, chart-wise, BTX is engaging in a huge breakout.
BioTime has a top position on on our shortlist.
